Find a Clinical Trial

Trial Description: This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT03579654
• Protocol ID: 18-076

Trial Description: This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer. The names of the study drugs involved in this study are: - Talazoparib - Tazemetostat

• Conditions: metastatic castration-resistant prostate cancer, metastatic prostate cancer
• Phase: I
• Trial ID: NCT04846478
• Protocol ID: 21-086

Trial Description: The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes. There are only approximately 150 men with a known BRCA1 or BRCA2 mutation in the UK. Research has shown that these men are at an increased risk of developing prostate cancer but more information is needed about the pathogenesis of prostate cancer in this defined group and the role of screening in these men. The study will offer annual PSA screening to these men to determine the incidence

• Conditions: prostate cancer in brca1 and brca2 carriers
• Phase: Not Applicable
• Trial ID: NCT00261456
• Protocol ID: 17-077

Trial Description: This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving

• Conditions: metastatic malignant neoplasm in the bone, prostate adenocarcinoma, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iva prostate cancer ajcc v8
• Phase: III
• Trial ID: NCT04513717
• Protocol ID: 21-031

Trial Description: This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

• Conditions: prostate adenocarcinoma, stage i prostate cancer ajcc v8, stage ii prostate cancer ajcc v8, stage iia prostate cancer ajcc v8, stage iib prostate cancer ajcc v8, stage iic prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iva prostate cancer ajcc v8
• Phase: III
• Trial ID: NCT04134260
• Protocol ID: 20-651

Trial Description: This is a prospective, randomized, open-label phase II study comparing cognitive outcomes between men with non-metastatic and metastatic castration-resistant prostate cancer (mCRPC or M0CRPC) treated with darolutamide or enzalutamide. Approximately 132 patients will be enrolled. Eligible patients will be randomized in a 1:1 fashion to treatment with enzalutamide 160 mg orally daily or darolutamide 600 mg orally twice daily, in combination with standard LHRH agonist based treatment. Cognitive assessments will be performed using modules from Cambridge Neuropsychological Test Automated Battery (CANTAB) an internationally recognized software for assessing cognitive function and impairment.

• Conditions: castrate resistant prostate cancer, metastatic prostate cancer, prostate cancer, prostate cancer metastatic
• Phase: II
• Trial ID: NCT04335682
• Protocol ID: 22-335

Trial Description: Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one novel androgen-receptor targeted therapy (i.e. Abiraterone acetate, Enzalutamide). Up to one taxane agent is permitted.

• Conditions: castration-resistant prostate cancer, metastatic prostate cancer, prostate cancer
• Phase: II
• Trial ID: NCT03554317
• Protocol ID: 19-096

Trial Description: The purpose of this study is to determine whether a 16-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among Black men with prostate cancer undergoing active surveillance. The name of the study intervention involved in this study is: Aerobic high-intensity interval training (HIIT) (training exercise intervention)

• Conditions: prostate cancer, prostatic neoplasms
• Phase: Not Applicable
• Trial ID: NCT05918263
• Protocol ID: 23-119

Trial Description: This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and advanced prostate cancers. The first phase of the study is to establish a recommended dose for the second phase. The names of the study drugs and interventions involved in this study are: - Darolutamide - Abemaciclib - Androgen deprivation therapy (ADT) - this includes several different treatments, including Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists It is expected that about 93 people will take part in the research study. Treatment is expected to last 6 months with a follow up period of up to 4.5 years.

• Conditions: metastatic prostate cancer, non-metastatic prostate cancer, prostate cancer
• Phase: I/II
• Trial ID: NCT05617885
• Protocol ID: 22-422

Trial Description: This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays role in prostate cancer development. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. Giving darolutamide with ADT may work better in eliminating or reducing the size of the cancer and/or prevent it from returning compared to ADT alone in patients with prostate cancer.

• Conditions: prostate carcinoma
• Phase: III
• Trial ID: NCT04484818
• Protocol ID: 22-136

Trial Description: The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT03716739
• Protocol ID: 18-733

Trial Description: This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study interventions involved in this study are: - LY2452473

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT02499497
• Protocol ID: 15-120

Trial Description: This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

• Conditions: breast cancer, metastatic prostate cancer, ovarian cancer, pancreatic cancer
• Phase: Not Applicable
• Trial ID: NCT04330716
• Protocol ID: 19-652

Trial Description: This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT03637543
• Protocol ID: 18-249

Trial Description: This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment. - The names of the study drug involved in this study is neratinib.

• Conditions: castration-resistant prostate cancer, metastatic prostate adenocarcinoma, prostate cancer, prostate cancer metastatic
• Phase: II
• Trial ID: NCT04781374
• Protocol ID: 20-659

Trial Description: This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer.

• Conditions: prostate cancer
• Phase: Not Applicable
• Trial ID: NCT03328091
• Protocol ID: 17-409

Trial Description: This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include three MRI scans (one before, one during, and one after standard of care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include: - Screening for eligibility - Three MRI scans

• Conditions: esophageal cancer, glioblastoma, magnetic resonance imaging, mri, pediatric glioblastoma multiforme, prostate cancer, radiotherapy, vulvar cancer
• Phase: I
• Trial ID: NCT04188535
• Protocol ID: 19-573

Trial Description: This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic prostate cancer. The trial is also testing the safety of the combination of abemaciclib with atezolizumab.

• Conditions: metastatic castration-resistant prostate cancer, prostate cancer
• Phase: II
• Trial ID: NCT04751929
• Protocol ID: 20-701

Trial Description: Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might predict if prostate cancer will return after this surgery. Objective: To test if a PET/CT scan before the prostate gland is removed can predict if prostate cancer will return. Also, to test if this approach is better or worse than the usual approach for prostate cancer. Eligibility: Men ages 18 and older with prostate cancer that appears to be contained within the prostate

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT03976843
• Protocol ID: 19-667

Trial Description: This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or apalutamide or who are second generation anti-androgen treatment naive, and who have not received chemotherapy for mCRPC. This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with either enzalutamide or abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy profiles.

• Conditions: metastatic castration-resistant prostate cancer, metastatic prostate cancer
• Phase: I/II
• Trial ID: NCT04179864
• Protocol ID: 21-105

Trial Description: The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). The names of the study intervention involved in this study is: • Supervised circuit training (aerobic and resistance exercise regimen)

• Conditions: metastatic prostate cancer, metastatic prostate carcinoma, prostate cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT06040125
• Protocol ID: 23-109

Trial Description: The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

• Conditions: prostatic neoplasms
• Phase: I
• Trial ID: NCT04428788
• Protocol ID: 20-367

Trial Description: This research study is studying the safety and tolerability of an investigational combination of drugs, radium-223 plus pembrolizumab as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: - Radium-223 - Pembrolizumab

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT03093428
• Protocol ID: 16-498

Trial Description: This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating androgen deprivation therapy (ADT) for prostate cancer

• Conditions: prostate cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT03070145
• Protocol ID: 16-515

Trial Description: This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT03141671
• Protocol ID: 16-623

Trial Description: The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.

• Conditions: prostate cancer
• Phase: III
• Trial ID: NCT04136353
• Protocol ID: 21-464

Trial Description: This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.

• Conditions: prostate cancer
• Phase: III
• Trial ID: NCT03009981
• Protocol ID: 17-384

Trial Description: The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce the chances of the cancer coming back in the future. These treatments include a hormone injection given monthly or every three months and the study drugs, which include abiraterone acetate, prednisone, and apalutamide. These medications are being used in combination with surgery and maybe radiotherapy because studies have shown that any single

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT03436654
• Protocol ID: 18-429

Trial Description: This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.

• Conditions: prostate cancer
• Phase: II
• Trial ID: NCT04025372
• Protocol ID: 19-202

Trial Description: This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.

• Conditions: prostate cancer
• Phase: Not Applicable
• Trial ID: NCT05804318
• Protocol ID: 22-687

Trial Description: The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.

• Conditions: prostate cancer
• Phase: III
• Trial ID: NCT03511664
• Protocol ID: 18-425

Trial Description: A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.

• Conditions: prostate cancer
• Phase: III
• Trial ID: NCT04186819
• Protocol ID: 20-073

Trial Description: This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at least 6, but no more than 12 months of hormonal therapy. The name of the study drugs involved in this study is: - LHRHA (luteinizing hormone-releasing hormone agonist or antagonist) - Abiraterone Acetate - Apalutamide - Prednisone

• Conditions: prostate cancer
• Phase: III
• Trial ID: NCT03777982
• Protocol ID: 18-530

Trial Description: This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

• Conditions: prostate cancer
• Phase: II/III
• Trial ID: NCT03706365
• Protocol ID: 19-212

Trial Description: This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits.

• Conditions: prostate cancer
• Phase: Not Applicable
• Trial ID: NCT03761160
• Protocol ID: 17-692

Trial Description: In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: - Implantation of a MR-guided microdevice

• Conditions: prostate cancer, radical prostatectomy
• Phase: Feasibility / Pilot
• Trial ID: NCT04399876
• Protocol ID: 19-599

Trial Description: The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it will also improve physical fitness and function, body composition, and outcomes such as quality of life, cancer symptoms, and self-esteem. Participants in this study will be randomly assigned to one of two groups: 1) Aerobic and resistance exercise, or 2) Usual care.

• Conditions: androgen deprivation therapy, prostate cancer, prostate cancer metastatic
• Phase: Not Applicable
• Trial ID: NCT05327465
• Protocol ID: 21-741

Trial Description: This phase Ib trial studies the side effects and best dose of niraparib when given together with radium Ra223 dichloride in treating subjects with prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels and has spread from the primary site to the bone. Radium Ra 223 dichloride, acts like calcium to target cancer in the bones and may deliver radiation directly to the bone tumors, limiting damage to the surrounding normal tissue. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving radium Ra 223 dichloride and niraparib may work better in treating subjects with hormone-resistant prostate cancer metastatic to the bone.

• Conditions: hormone-refractory prostate cancer, prostate carcinoma metastatic to the bone, stage iv prostate adenocarcinoma
• Phase: I
• Trial ID: NCT03076203
• Protocol ID: 17-698

Trial Description: The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.

• Conditions: prostatic neoplasms
• Phase: II
• Trial ID: NCT02854436
• Protocol ID: 16-493

Trial Description: The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA levels using standard PET/CT scans and participants will receive standard-of-care androgen receptor antagonist monotherapy. The names of the treatment interventions involved in this study are: - Androgen receptor antagonist monotherapy. - PSMA PET/CT scan It is expected that about 15 people will take part in this research study. Participation in this research study is expected to last about 4 weeks.

• Conditions: metastatic hormone-sensitive prostate cancer (mhspc), prostate adenocarcinoma, prostate cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT05683964
• Protocol ID: 22-441

Trial Description: This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

• Conditions: castration-resistant prostate carcinoma, metastatic prostate carcinoma, stage iv prostate cancer ajcc v8
• Phase: II
• Trial ID: NCT03517969
• Protocol ID: 19-715

Trial Description: This phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen receptor-pathway inhibitor therapy. The usual treatment for patients with metastatic prostate cancer is to receive hormonal medications including a medication to decrease testosterone levels in the body and a potent oral hormonal medication to block growth signals from male hormones (like testosterone) in the cancer cells. Patients whose cancer is responding exceptionally well to this therapy may take a break from these medications according to their doctor's guidance. This trial may help doctors determine if stopping treatment can allow for testosterone recovery.

• Conditions: castration-sensitive prostate carcinoma, metastatic prostate carcinoma, stage iv prostate cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8
• Phase: II
• Trial ID: NCT05241860
• Protocol ID: 22-465

Trial Description: A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

• Conditions: castration resistant prostate cancer (crpc), follicular lymphoma (fl), small cell lung cancer (sclc)
• Phase: I
• Trial ID: NCT03460977
• Protocol ID: 18-159

Trial Description: The overall goal of this study is to determine if implementing structured exercises prevent decline in muscle mass, muscle strength and physical function in men with prostate cancer undergoing androgen deprivation therapy (ADT). Our main hypothesis is that structured resistance exercise training in men undergoing ADT will preserve physical function assessed by loaded stair climbing power compared with the control group. The trial will also examine the efficacy of the exercise regimen on muscle strength, QOL and fatigue. The findings of this trial will lay the groundwork for definitive intervention trials to prevent frailty and falls in these men.

• Conditions: physical function, prostate cancer
• Phase: II
• Trial ID: NCT04485767
• Protocol ID: 20-193

Trial Description: This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease in PSA slope following treatment compared to men that do not supplement with MPX.

• Conditions: adenocarcinoma of the prostate
• Phase: III
• Trial ID: NCT03535675
• Protocol ID: 18-525

Trial Description: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

• Conditions: advanced solid tumors, metastatic breast cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer
• Phase: I/II
• Trial ID: NCT03568656
• Protocol ID: 21-430

Trial Description: The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.

• Conditions: metastatic castration-resistant prostate cancer
• Phase: II
• Trial ID: NCT03414034
• Protocol ID: 18-117

Trial Description: Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.

• Conditions: castration resistant metastatic prostate cancer
• Phase: II
• Trial ID: NCT04363164
• Protocol ID: 21-507

Trial Description: This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: - Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon). - Docetaxel - Nivolumab

• Conditions: hormone sensitive prostate cancer, metastasis prostate adenocarcinoma, prostate adenocarcinoma
• Phase: II
• Trial ID: NCT04126070
• Protocol ID: 19-384

Trial Description: The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients. The names of the study interventions involved in this study are: - Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom. - Unsupervised aerobic and resistance exercise (UNSUP) - home-based 16- week aerobic and resistance exercise. - Attention control (AC) - 16-week home-based stretching.

• Conditions: breast cancer, colorectal cancer, prostate cancer
• Phase: Not Applicable
• Trial ID: NCT05327452
• Protocol ID: 21-559